Author: sHq_LoGiNz

GALWAY, Ireland, June 4, 2026 /3BL/ – Medtronic, a global leader in healthcare technology, today announced its first cohort of Medtronic Spark Scholarship recipients, recognizing 100 exceptional students from low-income households pursuing careers in health tech. This marks a significant milestone in Medtronic Spark’s global 10-year initiative to propel 1 million students into health tech careers.

The inaugural scholarship cohort represents 12 home countries and was selected from a pool of more than 1,500 applicants across 42 countries. Each recipient receives:

• Financial support for educational expenses, renewable for up to four years
• Career building experiences, which may include Medtronic mentorship, coaching, networking support, and more
• Availability of an emergency support fund to close the gap when facing unexpected episodic hardships that can derail academic progress

“The Medtronic Spark Scholarship gives students from around the world an opportunity to pursue their passion for improving people’s lives,” said Dr. Sally Saba, President of Medtronic Foundation. “I’m inspired and humbled by their stories of grit, perseverance, and determination to seek an education that allows them to serve and heal others. By combining financial support with mentorship, career guidance, and additional services, we’re creating a holistic support system that removes barriers and empowers students to graduate and thrive in health tech careers.”

“I’m inspired by the challenge of turning breakthrough science into technologies people can trust, access, and benefit from,” said Nathan, a Medtronic Spark scholarship recipient studying biomedical engineering and finance at Washington University in St. Louis. “I hope to build and scale health innovations—especially in areas like neurotechnology.”

Medtronic will award up to 100 new scholarships each year over the next 10 years to students residing in 70+ eligible countries. Applications will re-open in October 2026.

“I have always dreamed of helping people in difficult situations achieve a better quality of life through science,” said Valeria, a Medtronic Spark scholarship recipient at the Instituto Teccnológico y de Estudios Superiores de Monterrey in Mexico. “Receiving the Medtronic Spark scholarship motivates me to continue pursuing this dream, to move forward with determination along the career path I am passionate about.”

Visit https://www.medtronicspark.com/scholarship/ to learn more and sign up to receive updates.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Justin Paquette
Public Relations
+1-612-271-7935

Ingrid Goldberg
Investor Relations
+1-763-505-2696

Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States 

• New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi
• New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood
• Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae

INDIANAPOLIS, June 4, 2026 /3BL/ – Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i

The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii

“New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods,” said Jeff Simmons, President and CEO, Elanco Animal Health. “We want to thank the FDA, EPA and USDA, for all their work to prepare for this threat. We’re committed to supporting our customers during this challenging time by delivering innovation, scientific expertise, and available resources to help treat New World screwworm and support the health and well-being of animals.”

With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, Elanco is working alongside the U.S. animal health industry to help them fight against this parasite, offering a portfolio of options for pets and livestock that can help treat New World screwworm larvae infestations.

Available Elanco Treatment and/or Prevention Options 

Negasunt Powder and Tanidil will be available only through the U.S. Animal Plant Health and Inspection Service (APHIS) and its National Veterinary Stockpile. They will be distributed in coordination with state animal health officials and federally recognized tribal agencies. In the near future, APHIS will share additional information about the requirements for use, including tracking and reporting requirements and required safety and personal protective equipment.

As New World screwworm enters the United States, Elanco is committed to working alongside producers as they continuously evolve management practices and to help them implement prevention and treatment protocols to use the right product at the right time.

To learn more about Elanco’s ongoing efforts and historical perspective on New World screwworm, please visit our previous coverage:

• Elanco’s Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock 
• Elanco’s Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs 
• Elanco’s Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats 
• Elanco’s Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs 

To learn more about New World screwworm (NWS) using the following resources:

• USDA NWS Alert and Fact Sheet 
• NCBA NWS Resources 
• FDA Information for Veterinarians on NWS 

i USDA Confirms Presence of New World Screwworm in the United States | Animal and Plant Health Inspection Service 
ii “New World Screwworm.” www.aphis.usda.gov, www.aphis.usda.gov/livestock-poultry-disease/cattle/ticks/screwworm.

PM-US-26-1137

About Elanco Animal Health 
Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

Indications for Credelio Quattro/Credelio Quattro-CA1 
Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.

Important Safety Information for Credelio Quattro/Credelio Quattro-CA1 
Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.

For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.

Emergency Use Authorization of Credelio (lotilaner) Chewable Tablets for New World Screwworm (NWS) 

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio (lotilaner) chewable tablets for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Credelio is not approved for this use.

Credelio (lotilaner) is approved for other uses in dogs and puppies.

For additional information on the EUA, please refer to the Credelio NWS Fact Sheet.

Limitations of Authorized Use 
Credelio (lotilaner) chewable tablets is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio (lotilaner) chewable tablets under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio 
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Important Safety Information for Credelio 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.

Emergency Use Authorization for Credelio CAT (lotilaner) for New World Screwworm (NWS) 
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio CAT (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens. Credelio CAT is not approved for this use.

Credelio CAT is approved for other uses.

For additional information on the EUA, please refer to the Credelio Cat NWS Fact Sheet.

Limitations of Authorized Use 
Credelio CAT (lotilaner) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio CAT (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio CAT 
Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations for one month in cats and kittens 8 weeks of age and older and weighing 2 pounds or greater.

Credelio CAT is also indicated for treatment and control of black-legged tick infestations for one month in cats and kittens 6 months of age and older and weighing 2 pounds or greater.

Important Safety Information for Credelio CAT 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, rapid breathing and vomiting. For complete safety information, please see Credelio CAT product label or ask your veterinarian.

Emergency Use Authorization of Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) for New World Screwworm (NWS)

WARNING: Neurotoxicity. Read full Fact Sheet for complete information.

• Coumaphos and propoxur can cause neurotoxicity. May be fatal if swallowed. May be fatal if inhaled. Harmful if absorbed through skin. Causes moderate eye irritation. Do not breathe dust. Avoid contact with eyes, skin, or clothing.
• Use only with appropriate personal protective equipment (PPE): coveralls worn over long-sleeve shirt and long pants, shoes, socks, and protective eyewear; chemical-resistant gloves made of barrier laminate, butyl rubber (≥ 14 mils), nitrile rubber (≥14 mils), neoprene rubber (>14 mils), natural rubber (≥14 mils), polyethylene, polyvinyl chloride (PVC) ≥14 mils, or Viton (>14 mils); and a minimum of a NIOSH-approved elastomeric half mask respirator consisting of protection factor (PF) 10 fitted with organic vapor (OV) cartridges and combination R or P filters; or a NIOSH-approved gas mask with OV canisters; or a NIOSH-approved powered air purifying respirator with OV cartridges and combination HE filters.
• This product is toxic to mammals, birds, fish, and aquatic invertebrates.

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product Negasunt Powder for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia homnivorax) larvae (myiasis) in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids, and captive wild, exotic, and zoo mammals. Negasunt Powder is not approved for this use.

For use by employees of federal, state, local, and federally recognized tribal agencies, and persons working under their authority and at their direction. Also for use by or on the order of a licensed veterinarian in NWS infested zones and adjacent surveillance zones as defined by the U.S. Department of Agriculture (USDA).

For additional information on the EUA and for complete safety information, please refer to the Negasunt Powder NWS Fact Sheet.

Limitations of Authorized Use 
It is a violation of federal law to use this drug product other than as directed in the authorized Fact Sheet.

Treated animals must not be slaughtered for human consumption within 28 days of the last treatment.

A milk discard time has not been established for this product; do not use in animals producing milk for human consumption.

A withdrawal period has not been established for this product in pre-ruminating calves; treated calves and calves born to treated cows must not be processed for veal.

Do not use in horses intended for human consumption. Do not use in domestic indoor pets (e.g., dogs, cats, rodents, rabbits) nor in residences. Do not use in birds. Do not use in free-ranging wildlife.

To avoid overexposure, each individual person cannot treat more than 3 large wounds (>2 inches diameter) a day or more than 30 small superficial wounds (≤2 inches diameter) a day (or an equivalent thereof) with Negasunt Powder or any other coumaphos-containing products.

Negasunt Powder is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Negasunt Powder under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.

Federal law prohibits the extra-label use of this drug.

Additional Important Safety Information 
Not for use in humans. Keep out of reach of children. Only handlers wearing required PPE may be in the area during application. Do not apply in a confined, non-ventilated area; provide thorough ventilation. Call a poison control center or doctor immediately for treatment advice if Negusant Powder is swallowed, inhaled, on skin or clothing, or in eyes. Sulfonamides are contraindicated in animals that are hypersensitive to them and in animals with severe renal or hepatic impairment. For external use only on animals. Do not contaminate water, feed, troughs, feed handling equipment, or milk or meat handling equipment. Use with caution in very young, weak, or debilitated animals. In the case of overdose, treat with atropine sulfate or pralidoxine chloride (2-PAM) as soon as possible. The most common adverse reactions associated with organophosphate and carbamate toxicity in animals include frequent urination and defecation, muscle twitching, and watering eyes.

Important Information about Tanidil 
Tanidil™ is an unregistered product for distribution and use only under a Section 18 emergency exemption. The Section 18 labeling must be in the possession of the user at the time of pesticide application. This product may only be used to prevent or control New World screwworm in and on animal wounds on labeled animal host species.

For use only by federal, state, local, and federally recognized tribal agencies, and persons working under their supervision; personnel at quarantine stations and areas; veterinarians; veterinarians or certified applicators at livestock and game facilities, zoos, wildlife facilities, animal rehabilitation centers; and wildlife professionals.

Read the entire label. This product must be used strictly in accordance with this label’s precautionary statements and use directions, as well as with all applicable state and federal laws and regulations. Please visit the Tanidil fact sheet for more information.

Use Period: This exemption is effective on April 27, 2026 and expires on April 27, 2029. No applications of Tanidil may be made under the emergency exemption before its effective date or after its expiration date.

Credelio, Credelio Quattro, Negasunt, Tanidil, Catron, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates 
 

Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States 

• New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi
• New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood
• Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae

INDIANAPOLIS, June 4, 2026 /3BL/ – Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i

The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii

“New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods,” said Jeff Simmons, President and CEO, Elanco Animal Health. “We want to thank the FDA, EPA and USDA, for all their work to prepare for this threat. We’re committed to supporting our customers during this challenging time by delivering innovation, scientific expertise, and available resources to help treat New World screwworm and support the health and well-being of animals.”

With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, Elanco is working alongside the U.S. animal health industry to help them fight against this parasite, offering a portfolio of options for pets and livestock that can help treat New World screwworm larvae infestations.

Available Elanco Treatment and/or Prevention Options 

Negasunt Powder and Tanidil will be available only through the U.S. Animal Plant Health and Inspection Service (APHIS) and its National Veterinary Stockpile. They will be distributed in coordination with state animal health officials and federally recognized tribal agencies. In the near future, APHIS will share additional information about the requirements for use, including tracking and reporting requirements and required safety and personal protective equipment.

As New World screwworm enters the United States, Elanco is committed to working alongside producers as they continuously evolve management practices and to help them implement prevention and treatment protocols to use the right product at the right time.

To learn more about Elanco’s ongoing efforts and historical perspective on New World screwworm, please visit our previous coverage:

• Elanco’s Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock 
• Elanco’s Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs 
• Elanco’s Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats 
• Elanco’s Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs 

To learn more about New World screwworm (NWS) using the following resources:

• USDA NWS Alert and Fact Sheet 
• NCBA NWS Resources 
• FDA Information for Veterinarians on NWS 

i USDA Confirms Presence of New World Screwworm in the United States | Animal and Plant Health Inspection Service 
ii “New World Screwworm.” www.aphis.usda.gov, www.aphis.usda.gov/livestock-poultry-disease/cattle/ticks/screwworm.

PM-US-26-1137

About Elanco Animal Health 
Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

Indications for Credelio Quattro/Credelio Quattro-CA1 
Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.

Important Safety Information for Credelio Quattro/Credelio Quattro-CA1 
Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.

For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.

Emergency Use Authorization of Credelio (lotilaner) Chewable Tablets for New World Screwworm (NWS) 

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio (lotilaner) chewable tablets for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Credelio is not approved for this use.

Credelio (lotilaner) is approved for other uses in dogs and puppies.

For additional information on the EUA, please refer to the Credelio NWS Fact Sheet.

Limitations of Authorized Use 
Credelio (lotilaner) chewable tablets is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio (lotilaner) chewable tablets under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio 
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Important Safety Information for Credelio 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.

Emergency Use Authorization for Credelio CAT (lotilaner) for New World Screwworm (NWS) 
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio CAT (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens. Credelio CAT is not approved for this use.

Credelio CAT is approved for other uses.

For additional information on the EUA, please refer to the Credelio Cat NWS Fact Sheet.

Limitations of Authorized Use 
Credelio CAT (lotilaner) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio CAT (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio CAT 
Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations for one month in cats and kittens 8 weeks of age and older and weighing 2 pounds or greater.

Credelio CAT is also indicated for treatment and control of black-legged tick infestations for one month in cats and kittens 6 months of age and older and weighing 2 pounds or greater.

Important Safety Information for Credelio CAT 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, rapid breathing and vomiting. For complete safety information, please see Credelio CAT product label or ask your veterinarian.

Emergency Use Authorization of Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) for New World Screwworm (NWS)

WARNING: Neurotoxicity. Read full Fact Sheet for complete information.

• Coumaphos and propoxur can cause neurotoxicity. May be fatal if swallowed. May be fatal if inhaled. Harmful if absorbed through skin. Causes moderate eye irritation. Do not breathe dust. Avoid contact with eyes, skin, or clothing.
• Use only with appropriate personal protective equipment (PPE): coveralls worn over long-sleeve shirt and long pants, shoes, socks, and protective eyewear; chemical-resistant gloves made of barrier laminate, butyl rubber (≥ 14 mils), nitrile rubber (≥14 mils), neoprene rubber (>14 mils), natural rubber (≥14 mils), polyethylene, polyvinyl chloride (PVC) ≥14 mils, or Viton (>14 mils); and a minimum of a NIOSH-approved elastomeric half mask respirator consisting of protection factor (PF) 10 fitted with organic vapor (OV) cartridges and combination R or P filters; or a NIOSH-approved gas mask with OV canisters; or a NIOSH-approved powered air purifying respirator with OV cartridges and combination HE filters.
• This product is toxic to mammals, birds, fish, and aquatic invertebrates.

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product Negasunt Powder for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia homnivorax) larvae (myiasis) in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids, and captive wild, exotic, and zoo mammals. Negasunt Powder is not approved for this use.

For use by employees of federal, state, local, and federally recognized tribal agencies, and persons working under their authority and at their direction. Also for use by or on the order of a licensed veterinarian in NWS infested zones and adjacent surveillance zones as defined by the U.S. Department of Agriculture (USDA).

For additional information on the EUA and for complete safety information, please refer to the Negasunt Powder NWS Fact Sheet.

Limitations of Authorized Use 
It is a violation of federal law to use this drug product other than as directed in the authorized Fact Sheet.

Treated animals must not be slaughtered for human consumption within 28 days of the last treatment.

A milk discard time has not been established for this product; do not use in animals producing milk for human consumption.

A withdrawal period has not been established for this product in pre-ruminating calves; treated calves and calves born to treated cows must not be processed for veal.

Do not use in horses intended for human consumption. Do not use in domestic indoor pets (e.g., dogs, cats, rodents, rabbits) nor in residences. Do not use in birds. Do not use in free-ranging wildlife.

To avoid overexposure, each individual person cannot treat more than 3 large wounds (>2 inches diameter) a day or more than 30 small superficial wounds (≤2 inches diameter) a day (or an equivalent thereof) with Negasunt Powder or any other coumaphos-containing products.

Negasunt Powder is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Negasunt Powder under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.

Federal law prohibits the extra-label use of this drug.

Additional Important Safety Information 
Not for use in humans. Keep out of reach of children. Only handlers wearing required PPE may be in the area during application. Do not apply in a confined, non-ventilated area; provide thorough ventilation. Call a poison control center or doctor immediately for treatment advice if Negusant Powder is swallowed, inhaled, on skin or clothing, or in eyes. Sulfonamides are contraindicated in animals that are hypersensitive to them and in animals with severe renal or hepatic impairment. For external use only on animals. Do not contaminate water, feed, troughs, feed handling equipment, or milk or meat handling equipment. Use with caution in very young, weak, or debilitated animals. In the case of overdose, treat with atropine sulfate or pralidoxine chloride (2-PAM) as soon as possible. The most common adverse reactions associated with organophosphate and carbamate toxicity in animals include frequent urination and defecation, muscle twitching, and watering eyes.

Important Information about Tanidil 
Tanidil™ is an unregistered product for distribution and use only under a Section 18 emergency exemption. The Section 18 labeling must be in the possession of the user at the time of pesticide application. This product may only be used to prevent or control New World screwworm in and on animal wounds on labeled animal host species.

For use only by federal, state, local, and federally recognized tribal agencies, and persons working under their supervision; personnel at quarantine stations and areas; veterinarians; veterinarians or certified applicators at livestock and game facilities, zoos, wildlife facilities, animal rehabilitation centers; and wildlife professionals.

Read the entire label. This product must be used strictly in accordance with this label’s precautionary statements and use directions, as well as with all applicable state and federal laws and regulations. Please visit the Tanidil fact sheet for more information.

Use Period: This exemption is effective on April 27, 2026 and expires on April 27, 2029. No applications of Tanidil may be made under the emergency exemption before its effective date or after its expiration date.

Credelio, Credelio Quattro, Negasunt, Tanidil, Catron, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates 
 

Laverstoke, Hampshire, UK, June 4, 2026 /3BL/ – The BOMBAY SAPPHIRE® Distillery has been recognised for its continued leadership in conservation and biodiversity protection as it announces its Silver recertification through Wildlife Habitat Council (WHC) Certification, powered by Tandem Global. 

The Hampshire-based distillery, which is owned by Bacardi, has held the Silver Certification continuously since 2023 – a milestone that made it the first spirits production site in the UK to achieve the standard. Established in 1989, WHC Certification continues to be the world’s only voluntary sustainability standard for businesses enhancing biodiversity and supporting conservation education on their sites.

Located on the banks of the River Test, a designated Site of Special Scientific Interest, the BOMBAY SAPPHIRE distillery continues to support local biodiversity through initiatives including wildflower planting for pollinators and the installation of fish and eel passes to help improve river connectivity and support native species migration. The renewed Silver Certification recognises the distillery’s ongoing work to protect and restore wetland and river habitats, alongside continued efforts in biodiversity monitoring and responsible water stewardship along one of the UK’s most environmentally sensitive waterways.

The distillery is a landmark of sustainable design from globally celebrated, visionary designer Thomas Heatherwick. Its design is rated “Outstanding” by BREEAM – the world’s leading sustainability assessment method for masterplanning – and more than 99% of its waste is recycled or converted into energy. Added to this, Bombay Sapphire is crafted using a unique blend of 10 botanicals from sustainably certified suppliers. 

Beyond its own biodiversity programmes, BOMBAY SAPPHIRE and the Laverstoke Distillery continue to champion broader environmental action. In late 2025, the site hosted the presentation of the 2025 E1 Blue Impact Championship, presented by BOMBAY SAPPHIRE. The award, from E1 – the world’s first all-electric raceboat Championship – recognises the team that delivered the strongest season-long contribution to protecting and restoring aquatic ecosystems, supporting E1’s mission to accelerate ocean conservation efforts.

“The BOMBAY SAPPHIRE Distillery has been carefully cultivated with sustainability in mind. Being a Grade II listed historic site as well as a Site of Special Scientific Interest, conservation and restoration have always been central to the distillery and its surrounding landscape. Consideration for the environment runs throughout our practices at BOMBAY SAPPHIRE; from the partners we choose, including becoming the Official Gin partner of the E1 Series – the world’s first all-electric race boat championship, to the team’s dedication to sustainable practices in the production of our gin,” says Rodolfo Nervi, Vice President Corporate Sustainability, Global Safety and Quality at Bacardi. “We are incredibly proud to retain the WHC Silver Certification, having become the first UK spirits production facility to receive the recognition in 2023. We look forward to continuing our work to support the local environment and deliver meaningful, measurable outcomes for the landscapes and waterways around us.”

The site also participates in the Anglers’ Riverfly Monitoring Initiative, working with local volunteers from the Watercress and Winterbournes Landscape Partnership Scheme to track invertebrate populations. This citizen science programme provides valuable long-term data on river health, helping guide conservation priorities and adaptive environmental management.

“BOMBAY SAPPHIRE Distillery is recognised as meeting the strict requirements of WHC Certification. Companies achieving WHC Certification, like Bacardi, are environmental leaders, voluntarily managing their lands to support sustainable ecosystems and the communities that surround them,” says Margaret O’Gorman, Chief Executive Officer, Tandem Global.

The distillery joins other Bacardi facilities globally that have achieved certification and recognition for environmental performance, including operations in Puerto Rico and Jacksonville, Florida, underscoring the company’s broader commitment to sustainability across its global footprint.

To learn more about how Bacardi is doing the right thing, visit www.bacardilimited.com/CS 

Enjoy BOMBAY SAPPHIRE® responsibly.

MEDIA CONTACT:

bacardi@mucklemediagroup.co.uk
T: +44 (0) 7411264860

spey.scot

NOTES TO EDITORS:

About BOMBAY SAPPHIRE Distillery

The BOMBAY SAPPHIRE Distillery, located at the historic Laverstoke Mill in Hampshire, offers visitors a unique glimpse into the world of gin production. Opened to the public in 2014, the distillery is renowned for its Vapour Infusion process and its iconic glasshouses, designed by Heatherwick Studios, which showcase the ten botanicals used in the gin. With a range of tours, tastings, and cocktail masterclasses, the distillery provides an immersive experience for gin enthusiasts. Visitors can also enjoy the onsite café, bar, and shop. 

About Bacardi Limited
Bacardi Limited, the world’s largest privately held international spirits company, produces, markets, and distributes spirits and wines. The Bacardi Limited portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, PATRÓN® tequila, GREY GOOSE® vodka, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, D’USSÉ® Cognac, ANGEL’S ENVY® American straight whiskey, and ST-GERMAIN® elderflower liqueur. Founded more than 164 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs approximately 8,000, operates production facilities in 10 countries and territories, and sells its brands in more than 160 markets. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on LinkedIn and Instagram.

About Tandem Global
Tandem Global (formerly Wildlife Habitat Council and World Environment Center) provides the know-how and the network to move business and the environment forward, together. They work across sectors and at all levels of organizations to facilitate long-term and lasting impact on all aspects of our natural world. Tandem Global connects leading thinking with practical solutions that positively impact climate, nature, and water – from field operations to boardrooms and beyond. Learn more at https://tandemglobal.org/

Laverstoke, Hampshire, UK, June 4, 2026 /3BL/ – The BOMBAY SAPPHIRE® Distillery has been recognised for its continued leadership in conservation and biodiversity protection as it announces its Silver recertification through Wildlife Habitat Council (WHC) Certification, powered by Tandem Global. 

The Hampshire-based distillery, which is owned by Bacardi, has held the Silver Certification continuously since 2023 – a milestone that made it the first spirits production site in the UK to achieve the standard. Established in 1989, WHC Certification continues to be the world’s only voluntary sustainability standard for businesses enhancing biodiversity and supporting conservation education on their sites.

Located on the banks of the River Test, a designated Site of Special Scientific Interest, the BOMBAY SAPPHIRE distillery continues to support local biodiversity through initiatives including wildflower planting for pollinators and the installation of fish and eel passes to help improve river connectivity and support native species migration. The renewed Silver Certification recognises the distillery’s ongoing work to protect and restore wetland and river habitats, alongside continued efforts in biodiversity monitoring and responsible water stewardship along one of the UK’s most environmentally sensitive waterways.

The distillery is a landmark of sustainable design from globally celebrated, visionary designer Thomas Heatherwick. Its design is rated “Outstanding” by BREEAM – the world’s leading sustainability assessment method for masterplanning – and more than 99% of its waste is recycled or converted into energy. Added to this, Bombay Sapphire is crafted using a unique blend of 10 botanicals from sustainably certified suppliers. 

Beyond its own biodiversity programmes, BOMBAY SAPPHIRE and the Laverstoke Distillery continue to champion broader environmental action. In late 2025, the site hosted the presentation of the 2025 E1 Blue Impact Championship, presented by BOMBAY SAPPHIRE. The award, from E1 – the world’s first all-electric raceboat Championship – recognises the team that delivered the strongest season-long contribution to protecting and restoring aquatic ecosystems, supporting E1’s mission to accelerate ocean conservation efforts.

“The BOMBAY SAPPHIRE Distillery has been carefully cultivated with sustainability in mind. Being a Grade II listed historic site as well as a Site of Special Scientific Interest, conservation and restoration have always been central to the distillery and its surrounding landscape. Consideration for the environment runs throughout our practices at BOMBAY SAPPHIRE; from the partners we choose, including becoming the Official Gin partner of the E1 Series – the world’s first all-electric race boat championship, to the team’s dedication to sustainable practices in the production of our gin,” says Rodolfo Nervi, Vice President Corporate Sustainability, Global Safety and Quality at Bacardi. “We are incredibly proud to retain the WHC Silver Certification, having become the first UK spirits production facility to receive the recognition in 2023. We look forward to continuing our work to support the local environment and deliver meaningful, measurable outcomes for the landscapes and waterways around us.”

The site also participates in the Anglers’ Riverfly Monitoring Initiative, working with local volunteers from the Watercress and Winterbournes Landscape Partnership Scheme to track invertebrate populations. This citizen science programme provides valuable long-term data on river health, helping guide conservation priorities and adaptive environmental management.

“BOMBAY SAPPHIRE Distillery is recognised as meeting the strict requirements of WHC Certification. Companies achieving WHC Certification, like Bacardi, are environmental leaders, voluntarily managing their lands to support sustainable ecosystems and the communities that surround them,” says Margaret O’Gorman, Chief Executive Officer, Tandem Global.

The distillery joins other Bacardi facilities globally that have achieved certification and recognition for environmental performance, including operations in Puerto Rico and Jacksonville, Florida, underscoring the company’s broader commitment to sustainability across its global footprint.

To learn more about how Bacardi is doing the right thing, visit www.bacardilimited.com/CS 

Enjoy BOMBAY SAPPHIRE® responsibly.

MEDIA CONTACT:

bacardi@mucklemediagroup.co.uk
T: +44 (0) 7411264860

spey.scot

NOTES TO EDITORS:

About BOMBAY SAPPHIRE Distillery

The BOMBAY SAPPHIRE Distillery, located at the historic Laverstoke Mill in Hampshire, offers visitors a unique glimpse into the world of gin production. Opened to the public in 2014, the distillery is renowned for its Vapour Infusion process and its iconic glasshouses, designed by Heatherwick Studios, which showcase the ten botanicals used in the gin. With a range of tours, tastings, and cocktail masterclasses, the distillery provides an immersive experience for gin enthusiasts. Visitors can also enjoy the onsite café, bar, and shop. 

About Bacardi Limited
Bacardi Limited, the world’s largest privately held international spirits company, produces, markets, and distributes spirits and wines. The Bacardi Limited portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, PATRÓN® tequila, GREY GOOSE® vodka, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, D’USSÉ® Cognac, ANGEL’S ENVY® American straight whiskey, and ST-GERMAIN® elderflower liqueur. Founded more than 164 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs approximately 8,000, operates production facilities in 10 countries and territories, and sells its brands in more than 160 markets. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on LinkedIn and Instagram.

About Tandem Global
Tandem Global (formerly Wildlife Habitat Council and World Environment Center) provides the know-how and the network to move business and the environment forward, together. They work across sectors and at all levels of organizations to facilitate long-term and lasting impact on all aspects of our natural world. Tandem Global connects leading thinking with practical solutions that positively impact climate, nature, and water – from field operations to boardrooms and beyond. Learn more at https://tandemglobal.org/

CONSTANŢA, Romania, June 4, 2026 /3BL/ – DP World has signed an agreement with French research organisation Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA) and strategy specialist TerraWater Institute to launch a feasibility study into how Small Modular Reactor (SMR) technology could help meet the long-term energy needs, growth and decarbonisation of the Port of Constanța in Romania.

As ports electrify and grow, DP World sees access to reliable, low-carbon energy as critical to future competitiveness. Rising demand from electrified equipment, shore power, AI data centres, residential heating and industrial activity is placing greater pressure on existing energy systems, driving demand for stable and scalable power. Nuclear energy, including SMRs, has the potential to provide consistent, low-carbon electricity for port operations and wider industrial use.

Romania is a long-standing leader in nuclear energy in Europe, with decades of operational experience and a strong focus on energy security and decarbonisation aligned with EU priorities.

The study will model projected energy demand at the Port of Constanța from 2030 to 2050, evaluate integrated low-carbon energy systems, and assess the technical, strategic and economic feasibility of nuclear-based solutions. It will also examine safety standards and considerations for surrounding communities, drawing on CEA’s expertise in SMR design and nuclear safety, in line with DP World’s commitment to a “zero harm” approach across all its operations.

The study is intended to inform future decision-making on how best to meet long-term energy needs for the port and the wider economy. Any future development would be subject to further technical assessment, regulatory review and stakeholder engagement.

Nicholas Mazzei, VP Sustainability – Europe, DP World, said: “DP World sees the transition to a net zero economy not only as an environmental imperative, but as a driver of future growth across global trade. Nuclear SMRs are not just energy projects for our ports, they are a competitive infrastructure differentiator. This study will help us better understand how nuclear energy can strengthen operational resilience and help meet rising demand. Across Europe, nuclear energy is increasingly recognised as a resilient and cost-effective solution with the potential to underpin the next generation of industrial activity and the supply chains.”

Myrto Tripathi, General Director, TerraWater Institute, said: “Ports sit at the intersection of industry, energy systems, and communities. This study is about understanding how future low-carbon energy systems could be designed to meet complex and evolving demands, while maintaining high standards of safety and environmental performance. For energy as for everything, offer should not shape demand and should provide opportunities rather than dictate terms. Industries needs have to be understood, assessed and met, while decarbonizing. This is the only energy paradigm we should strive for and what we are aiming to demonstrate with this study, thanks to nuclear.”

Stéphane Sarrade, Directeur des Programmes Énergies, CEA, said: “This study brings together expertise in nuclear technology and energy systems to assess how small modular reactors could be integrated into a real port environment. By working with DP World and TerraWater, we are applying advanced modelling and analysis to better understand how these solutions could support reliable, low-carbon energy for ports.”

This work builds on DP World’s broader exploration of nuclear energy across its portfolio, including a memorandum of understanding signed last year as the company explores the role of nuclear energy in its UK ports. Together, these initiatives reflect DP World’s ambition to advance new energy solutions that support port growth, reinforce long-term energy security and accelerate Europe’s industrial transition.

For more information see DP World’s Sustainability Mission.

END

About DP World

DP World is reshaping the future of global trade to improve lives everywhere. Operating across six continents with a team of over 125,000 employees, we combine global infrastructure and local expertise to deliver seamless supply chain solutions. From Ports and Terminals to Marine Services, Logistics and Technology, we leverage innovation to create better ways to trade, minimising disruptions from the factory floor to the customer’s door.

DP World’s European network spans over 250 locations in more than 30 countries, including deep-sea ports, inland terminals, rail hubs and warehousing facilities. Through sustained investment in infrastructure, technology and people, we support more than 26,000 jobs and enable smarter, faster and more resilient trade across the continent.

Our global partnerships in golf, cricket, Formula 1 and sailing come to life across Europe – from the British Grand Prix to SailGP in Spain and the Turkish Open to name a few. These platforms allow us to demonstrate how logistics powers performance, connects communities and unlocks new possibilities.

WE MAKE TRADE FLOW

Rockwell Automation is working with Liquats Vegetals, a Spain-based producer of plant-based beverages, to support the digitalization of manufacturing operations at Liquats’ production facilities.

The collaboration is focused on improving process visibility, operational consistency, and energy transparency in response to growing production complexity in the plant‑based food industry, where manufacturers are managing a wider range of formulations, tighter resource constraints, and increasing expectations around sustainability and traceability.

“Manufacturers in Spain are operating in environments where production flexibility, data visibility and efficient use of resources are becoming essential,” said Jose Paredes, country director, Spain, Rockwell Automation. “Working with companies such as Liquats Vegetals reflects how industrial organizations are using digital transformation to gain better insight into their operations and support more informed, day-to-day decision making on the plant floor.”

As demand for plant-based beverages continues to grow, Liquats Vegetals is facing increasing requirements for flexible production lines, frequent product changeovers, and tighter control over resource consumption. Liquats has been advancing the digital transformation of its plants to improve operational visibility and to better understand energy and utility usage across production processes, including how production performance and resource consumption interact across processing and packaging operations.

Various Rockwell technologies are supporting Liquats Vegetals’ efforts to increase process consistency, operational visibility and energy transparency across its production facilities, including:

• The PlantPAx® distributed control system (DCS) to support more flexible process control across multiple formulations and frequent product changeovers, helping maintain consistent beverage quality
• The FactoryTalk® Energy Manager application to provide real‑time visibility into energy and utility consumption at the plant level, helping operations teams better understand usage patterns, detect anomalies, and support more informed actions related to energy efficiency and resource stewardship
• The DataMosaix™ industrial DataOps solution to consolidate production, energy, and sustainability data into a unified view, enabling Liquats to more effectively analyze performance, improve traceability, identify improvement opportunities, and support informed, day‑to‑day decision‑making across manufacturing operations.

By combining real‑time operational and energy data, the digitalization initiative supports Liquats Vegetals’ broader sustainability approach, helping translate energy transparency into practical insights that inform daily operational decisions and ongoing efforts to reduce environmental impact while maintaining product integrity.

“As our production environment becomes more complicated, having reliable and centralized operational data is essential,” said Tasio Corachán Masriera, director of processes and continuous improvement at Liquats Vegetals. “Digital transformation of key areas of the plant helps us better understand process variability, energy consumption, and operating costs, enabling more informed decisions and continuous improvement across our manufacturing operations.”

Liquats Vegetals operates production facilities in Catalonia and supplies a broad customer base that includes major Spanish retailers, foodservice operators and international distribution partners. The company’s manufacturing activities span multiple product categories and formulations, requiring adaptable production systems and close control over quality and resource use.

Learn more about Rockwell Automation sustainability priorities and outcomes: https://www.rockwellautomation.com/en-us/sustainability.html

by Kitty Broihier

Originally published on Guiding Stars Health & Nutrition News

The Mediterranean Diet is perennially popular, in large part because of the delicious, plant-forward cuisine of the region. It’s also consistently rated as one of the most healthy eating patterns in the world. There are many significant benefits to this style of eating. It supports heart health and assists with weight management. It also helps fight chronic inflammation in the body, and may even enhance longevity. But here’s something you might not know about the Mediterranean Diet: many of its health impacts are tied to its influence on gut health.

How Is the Mediterranean Diet Good for the Gut?

A healthy gut drives health benefits around the body—not just in the digestive system. And there are several ways that the Mediterranean eating pattern promotes both healthy digestion and gut function.

It Increases Diversity of Gut Microbiota. Trillions of microorganisms live in our digestive systems, and this community is extremely diverse (this is a good thing). Together, these organisms are responsible for physiological processes that influence metabolic and immunological health. The intestinal microbiota even protects the body against invading, dangerous microbes. Several studies have analyzed the Mediterranean eating style on the microbiota. And they show that, although individual responses can vary, following this type of diet promotes a healthy balance of bacteria in the microbiota. The overall effect? Improvement in processes related to gut health, inflammation, obesity and metabolic syndrome, and neurodegenerative diseases. Generally, the more diverse the population of bacteria in the gut, the more able it is to keep you healthy.

It Provides Prebiotics for Gut Bacteria. In most studies, people who follow the Mediterranean diet develop different gut microbiota than those who consume typical Western diets. The contribution of plentiful fiber, roughly 14g per 1000 calories, is likely part of the reason. Some fibers from our food can serve as food for the bacteria in the digestive tract—these are called prebiotic fibers. Prebiotic fibers are prominent in the Mediterranean diet, and in fact, most high-fiber foods contain some prebiotic fibers. In response to the fiber, the bacteria produce short-chain fatty acids (SCFA) in the colon. The benefits of SCFA production have been widely studied, but there is still lots to learn about these compounds. So far, some of the strongest research shows they likely play beneficial roles in:

• Decreasing inflammation and fighting chronic diseases that stem from it
• Strengthening the intestinal barrier
• Supporting the immune system
• Contributing several anti-obesity effects

It Supports a Healthy Balance of Gut Bacteria. Probiotics are live bacteria with health benefits. When our digestive tract is populated with adequate numbers of “good” bacteria, the microbiota works well, and our digestive systems hum along with no special attention needed. However, when there aren’t enough “good” bacteria (or when one type dominates), the imbalance—called dysbiosis—can cause a variety of problems. Everything from diarrhea or constipation to more complicated issues like bowel diseases and bacterial infections are more likely when gut bacteria are out of balance. Fermented foods, common in the Mediterranean Diet, are excellent sources of probiotics.

Which Mediterranean Diet Foods Boost Gut Health? 

It just so happens that most Mediterranean Diet foods are not just healthy, but good for your gut too! However, eating in the Mediterranean style does vary, since there are a number of countries in the region. This allows you to personalize your Mediterranean eating plan a bit while still maintaining some of the healthy basics. In general, the following foods are on a Mediterranean table every day if you want to emphasize gut-healthy foods:

• Legumes, nuts, seeds
• Whole grains
• A wide variety of fruits and vegetables
• Yogurt and other fermented dairy products
• Minimally processed, extra-virgin olive oil
• Seafood, especially those high in omega-3 fatty acids

About Guiding Stars

Guiding Stars is an objective, evidence-based, nutrition guidance program that evaluates foods and beverages to make nutritious choices simple. Products that meet transparent nutrition criteria earn a 1, 2, or 3 star rating for good, better, and best nutrition. Guiding Stars can be found in more than 2,000 grocery stores, in Circana’ Attribute Marketplace, and through the Guiding Stars Food Finder app.

Image by Freepik

Key Takeaways:

• EHS maturity is less about company size or certifications and more about the ability to manage risk consistently through growth, change, and operational complexity.
• Organizations often operate across multiple stages of EHS maturity at once, depending on location, function, and business activity.
• Leadership engagement, shared ownership, and actionable data are common indicators of more mature and sustainable EHS programs.
• Programs built solely around compliance can become difficult to sustain as organizations expand, acquire new operations, or face evolving regulatory expectations.
• Overly complex EHS systems can reduce engagement and weaken implementation, making scalability and practicality just as important as technical rigor.
• Incremental, high-impact improvements tied to a long-term vision are often more effective than launching too many global initiatives at once.

 

For many organizations, Environmental, Health, and Safety (EHS) efforts begin and sometimes end with regulatory compliance. Regulations define what is required, and programs are built to meet those obligations. While regulatory compliance should always be a central pillar of an EHS program, over time different questions emerge:

• Can we sustain this?
• Is our management system fit for purpose and built to scale for our organization?
• Are we truly doing what is necessary to manage EHS risks within our organization?

These questions mark the transition from compliance to capacity. This transition often occurs as organizations begin to grow, expand locations, experience leadership changes, integrate acquisitions, or simply realize that maintaining EHS performance becomes more difficult as operational complexity increases.

While compliance focuses on simply meeting defined requirements, capacity is about having the structures, capabilities, and ownership in place to manage risk consistently and in a seamless, achievable manner, not only today but also as the organization grows, changes, or faces new challenges.

This greater capacity and readiness for the future are the hallmarks of a mature EHS program. To reach that stage, it is crucial for organizations to recognize where they are now, what is realistic to maintain, and where to focus next.

 

What EHS Maturity Really Means

EHS maturity is not a function of an organization’s size or global footprint, nor is it a function of how many certifications the company has. A small organization with a well-developed and integrated management system can operate at a high level of maturity, just as a large name-brand global organization may struggle to attain it. Conversely, organizations can appear mature on paper through extensive documentation or certification while still struggling with implementation consistency, ownership, or operational integration.

At its core, EHS maturity reflects an organization’s ability to consistently identify, evaluate, and manage risk not just once, but repeatedly over time. Mature EHS programs demonstrate repeatability, clarity of ownership, and resilience with changing conditions, such as leadership transitions, location additions, operations evolutions, or changes in regulatory expectations and requirements.

In practical terms, maturity shows up in how well EHS processes continue to function when attention shifts elsewhere, priorities compete, or resources tighten.

 

The 4 Stages of EHS Maturity

While maturity exists on a continuum, it is often helpful to think in terms of a few broad stages:

1. Reactive

EHS activities are driven by incidents, regulatory findings and citations, or external pressure. Efforts tend to be informal and inconsistent, with limited to no structure or forward planning, and are heavily dependent on individual effort rather than structured systems.

2. Compliant

Programs are built to meet base regulatory requirements. Responsibilities are assigned, documentation exists, and audits are completed. The focus is primarily on “checking the box” rather than improving the system, the health and safety of employees and other parties, or the environment.

3. Proactive

The organization is looking at leading indicators, completing a trend analysis of collected EHS metrics/data, and developing proactive prevention strategies to guide decisions. Risks are identified earlier, and corrective actions are prioritized before incidents occur. Operational and business decisions increasingly consider EHS impacts earlier in the process rather than after problems emerge.

4. Integrated

The pinnacle of EHS maturity—a state that many organizations strive for, but few fully attain. In this stage, EHS is seamlessly integrated into how the organization operates. Not as a bolt on, not living alongside operations, not as a blocker or something perceived as unnecessary, but baked into the company culture. Leaders share ownership, employees are engaged and actively participate in EHS, data informs business decisions, and systems are maintained as part of normal operations rather than as a separate initiative.

Organizations do not move through these stages overnight, and many operate across multiple stages at once depending on location, function, or variable operations.

 

Key Indicators of a Mature EHS Program

As EHS maturity grows, several meaningful shifts tend to occur.

• Leadership involvement increases: EHS moves from being viewed as a technical function to a leadership responsibility. Leaders reinforce and embody expectations, allocate resources to ensure success, and participate in top management reviews. Leadership is not simply involved after something goes wrong, but as part of routine operations.
• Data becomes actionable: Rather than collecting data solely for reporting, organizations use it to identify patterns, prioritize risks, and guide improvement. Metrics evolve from lagging indicators to tools for decision-making with a strong focus on leading indicators.
• Ownership extends beyond EHS: Responsibility for managing risk is not exclusively owned by the EHS function but is shared across operations from employees, supervisors and managers to human resources, security, operational business units and more. There is strong multi-functional EHS governance that is routinely engaged. EHS teams enable, guide, and continuously improve the system, but they are no longer the sole owners of outcomes.
• Systems are maintained and continuously improved: Procedures, training, and tools are routinely reviewed and updated, not launched and left to languish. Change management becomes intentional, helping systems remain effective and relevant even as the organization grows and evolves.

Together, these shifts strengthen an organization’s capacity to manage risk without requiring constant intervention or rework and help EHS to succeed naturally rather than as an afterthought.

 

Why Maturity Matters More Than Perfection

One of the most common pitfalls in EHS programs is over-engineering and over-complicating them. Organizations often develop systems, programs, and processes that look or sound impressive but are difficult to sustain or are simply not user-friendly. Over-engineered systems can create administrative burden, reduce engagement, and ultimately weaken implementation. Focusing on maturity and slow iterative growth instead of perfection helps organizations avoid this trap.

Progress does not require adopting every best practice at once. It requires choosing steps that match the organization’s current capacity while building toward the next level.

 

How to Improve EHS Maturity: A Practical Approach

Don’t bite off more than you can chew. Unless you are an organization with unlimited resources (I have yet to meet this company, and I frequently consult for Fortune 10 companies), prioritize your highest risks and achievable projects that will have the greatest impact. Succeeding at a handful of high-impact initiatives at once is far more meaningful than doing a middling job or—worse—failing to meet the goals of a multitude of initiatives at once. Far too often an organization will get bogged down trying to complete 30 or more global initiatives at once; for most, this is simply untenable.

Ensure that the priorities you are tackling are part of a wider vision and game plan. Each initiative or project should be a purposeful stepping stone to your organization’s end vision. Ensure that this vision is clearly defined as it will differ from organization to organization. The goal of EHS maturity is not to become “best in class” overnight. It is to create forward momentum, strengthening the systems, ownership, and capabilities needed to manage risk consistently over time.

By shifting the focus from compliance alone to sustainable capacity, organizations can build EHS programs that not only meet requirements, but continue to perform as the business grows, changes, and faces new challenges. Looking for help building your EHS programs? Reach out to our team for help today! 

During our National Training Conference in Tampa, more than 280 Subaru volunteers assembled over 1,000 pet adoption kits, each filled with toys, treats, Subaru bandanas, and essential supplies to help pets begin their next chapter. These kits were proudly donated to the Humane Society of Tampa Bay and are now being distributed to adoption locations on both sides of the bay – supporting families and pets as they find each other. 

Showing love to pets in need is a core pillar of the Subaru Love Promise, and we’re grateful to have teammates who lead with heart and purpose wherever we go.